Eureka Genomics Launches a Novel Custom Genotyping Service
News May 09, 2012
Eureka Genomics (EG) has launched a custom service for the detection of a moderate number of markers in a large sample number of samples; a low cost, low density marker assay (LDMA).
The platform is designed for the customized detection of hundreds of SNPs in thousands of samples using a single lane of an Illumina next generation sequencer. Instead of making large amounts of data on small numbers of sample, LDMA makes very focused data on a large number of samples.
According to EG, this service can be used very broadly and provides researchers with an affordable tool to validate the putative makers from GWA and other types of studies. This custom service utilizes the power of next generation sequencing data generation and EG’s proprietary bioinformatics and can be applied to the detection of SNPs, CNV, presence/absence and methylation. It can be used with DNA or RNA, with model organisms, commercial organisms or exotic organisms, and with complete or incomplete genomes.
“With this new service, individual researchers can harness the cost effectiveness of next generation sequencers to produce massive amounts of data that is focused on their biological sequences and SNPs of interest over large numbers of samples,” said Heather Koshinsky, CSO, Eureka Genomics. “Instead of spending resources on all the extra data that accompany traditional arrays and sequencing, with the LDMA service researchers can focus on their biomarkers of interest and move more quickly and cost effectively to understand their biological question or disease.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.